Literature DB >> 9016602

In the presence of subunit A inhibitors DNA gyrase cleaves DNA fragments as short as 20 bp at specific sites.

H Gmünder1, K Kuratli, W Keck.   

Abstract

A key step in the supercoiling reaction is the DNA gyrase-mediated cleavage and religation step of double-stranded DNA. Footprinting studies suggest that the DNA gyrase binding site is 100-150 bp long and that the DNA is wrapped around the enzyme with the cleavage site located near the center of the fragment. Subunit A inhibitors interrupt this cleavage and resealing cycle and result in cleavage occurring at preferred sites. We have been able to show that even a 30 bp DNA fragment containing a 20 bp preferred cleavage sequence from the pBR322 plasmid was a substrate for the DNA gyrase-mediated cleavage reaction in the presence of inhibitors. This DNA fragment was cleaved, although with reduced efficiency, at the same sites as a 122 bp DNA fragment. A 20 bp DNA fragment was cleaved with low efficiency at one of these sites and a 10 bp DNA fragment was no longer a substrate. We therefore propose that subunit A inhibitors interact with DNA at inhibitor-specific positions, thus determining cleavage sites by forming ternary complexes between DNA, inhibitors and DNA gyrase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9016602      PMCID: PMC146451          DOI: 10.1093/nar/25.3.604

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  34 in total

Review 1.  DNA topoisomerase-trapping antitumour drugs.

Authors:  G Capranico; F Zunino
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

Review 2.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

3.  Covalent bonds between protein and DNA. Formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA.

Authors:  Y C Tse; K Kirkegaard; J C Wang
Journal:  J Biol Chem       Date:  1980-06-25       Impact factor: 5.157

Review 4.  Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.

Authors:  N Osheroff; A H Corbett; S H Elsea; M Westergaard
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Interaction between DNA gyrase and its cleavage site on DNA.

Authors:  A Morrison; N P Higgins; N R Cozzarelli
Journal:  J Biol Chem       Date:  1980-03-10       Impact factor: 5.157

6.  Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.

Authors:  G Capranico; K W Kohn; Y Pommier
Journal:  Nucleic Acids Res       Date:  1990-11-25       Impact factor: 16.971

Review 7.  DNA gyrase: structure and function.

Authors:  R J Reece; A Maxwell
Journal:  Crit Rev Biochem Mol Biol       Date:  1991       Impact factor: 8.250

8.  Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.

Authors:  C H Freudenreich; K N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

9.  Light-induced expression of the chimeric chalcone synthase-NPTII gene in tobacco cells.

Authors:  Hildegard Kaulen; Jeff Schell; Fritz Kreuzaler
Journal:  EMBO J       Date:  1986-01       Impact factor: 11.598

10.  Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors.

Authors:  C H Freudenreich; K N Kreuzer
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

View more
  10 in total

1.  Type IIA topoisomerase inhibition by a new class of antibacterial agents.

Authors:  Benjamin D Bax; Pan F Chan; Drake S Eggleston; Andrew Fosberry; Daniel R Gentry; Fabrice Gorrec; Ilaria Giordano; Michael M Hann; Alan Hennessy; Martin Hibbs; Jianzhong Huang; Emma Jones; Jo Jones; Kristin Koretke Brown; Ceri J Lewis; Earl W May; Martin R Saunders; Onkar Singh; Claus E Spitzfaden; Carol Shen; Anthony Shillings; Andrew J Theobald; Alexandre Wohlkonig; Neil D Pearson; Michael N Gwynn
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

2.  DNA gyrase can cleave short DNA fragments in the presence of quinolone drugs.

Authors:  M E Cove; A P Tingey; A Maxwell
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

3.  Sequence specific interaction of Mycobacterium smegmatis topoisomerase I with duplex DNA.

Authors:  T Bhaduri; D Sikder; V Nagaraja
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

4.  Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis.

Authors:  H Gmuender; K Kuratli; C P Gray; W Keck; S Evers
Journal:  Genome Res       Date:  2001-01       Impact factor: 9.043

5.  Panel of Bacillus subtilis reporter strains indicative of various modes of action.

Authors:  Bernd Hutter; Christina Fischer; Alexander Jacobi; Christoph Schaab; Hannes Loferer
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

6.  Quinolone-binding pocket of DNA gyrase: role of GyrB.

Authors:  Jonathan Heddle; Anthony Maxwell
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase-DNA complex.

Authors:  Christian G Noble; Faye M Barnard; Anthony Maxwell
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  The pentapeptide-repeat protein, MfpA, interacts with mycobacterial DNA gyrase as a DNA T-segment mimic.

Authors:  Lipeng Feng; Julia E A Mundy; Clare E M Stevenson; Lesley A Mitchenall; David M Lawson; Kaixia Mi; Anthony Maxwell
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

Review 9.  Exploiting bacterial DNA gyrase as a drug target: current state and perspectives.

Authors:  Frédéric Collin; Shantanu Karkare; Anthony Maxwell
Journal:  Appl Microbiol Biotechnol       Date:  2011-09-09       Impact factor: 4.813

10.  Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.

Authors:  Dirk Strumberg; John L Nitiss; Jiaowang Dong; Jerrylaine Walker; Marc C Nicklaus; Kurt W Kohn; Jonathan G Heddle; Anthony Maxwell; Siegfried Seeber; Yves Pommier
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.